The effect of obesity on antibiotic treatment failure: A historical cohort study

Pharmacoepidemiology and Drug Safety

Volumn 22, Issue 9, 2013, Pages 970-976

  Longo, Cristina ^a   Bartlett, Gillian ^a   Macgibbon, Brenda ^b   Mayo, Nancy ^c   Rosenberg, Ellen ^a   Nadeau, Lyne ^d   Daskalopoulou, Stella S ^a  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

^c RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Antibiotics; Infection; Obesity; Pharmacoepidemiology; Treatment failure

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; PENICILLIN V;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIBIOTIC TREATMENT FAILURE; ARTICLE; BODY WEIGHT; CLINICAL ASSESSMENT; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DATA BASE; DRUG TREATMENT FAILURE; FEMALE; GASTROINTESTINAL INFECTION; HEALTH CARE MANAGEMENT; HEALTH SURVEY; HOSPITALIZATION; HUMAN; INCIDENCE; INFECTION; INFORMED CONSENT; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY; OBESITY; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR; SAMPLE SIZE; SEASONAL INFLUENZA; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ANTIBIOTICS; INFECTION; OBESITY; PHARMACOEPIDEMIOLOGY; TREATMENT FAILURE;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BODY MASS INDEX; COHORT STUDIES; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; OBESITY; PHARMACOEPIDEMIOLOGY; RISK FACTORS; SOCIOECONOMIC FACTORS; TREATMENT FAILURE; YOUNG ADULT;

EID: 84882650700     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3461     Document Type: Article

References (40)

1. World Health Organization. Obesity and Overweight, 2006.
2. Wilborn C, Beckham J, Campbell B, et al. Obesity: prevalence, theories, medical consequences, management, and research directions. J Int Soc Sports Nutr 2005; 2: 4-31.
3. Lau DC, Douketis JD, Morrison KM, Hramiak IM, Sharma AM, Ur E. 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]. Can Med Assoc J 2007; 176(8): S1-13.
4. Stein CJ, Colditz GA. The epidemic of obesity. J Clin Endocrinol Metabol 2004; 89(6): 2522-2525.
5. Bertakis KD, Azari R. Obesity and the use of health care services. Obes Res 2005; 13(2): 372-379.
6. Falagas ME, Kompoti M. Obesity and infection. Lancet Infect Dis 2006; 6(7): 438-446.
7. Counterweight Project Team. The impact of obesity on drug prescribing in primary care. Br J Gen Pract 2005; 55(519): 743-749.
8. Peterson I, Hayward AC. Antibacterial prescribing in primary care. J Antimicrob Chemother 2007; 60(1): i43-47.
9. Falagas ME, Karageorgopoulos DE. Adjustment of dosing of antimicrobial agents for bodyweight in adults. Lancet 2010; 375(9710): 248-251.
10. Falagas ME, Athanasoulia AP, Peppas G, Karageorgopoulos DE. Effect of body mass index on the outcome of infections: a systematic review. Obes Rev 2009; 10(3): 280-289.
11. Blouin RA, Warren GW. Pharmacokinetic considerations in obesity. J Pharm Sci 1999; 88(1): 1-7.
12. Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet 2000; 39(3): 215-231.
13. Nawaratne S, Brien JE, Seeman E, et al. Relationships among liver and kidney volumes, lean body mass and drug clearance. Br J Clin Pharmacol 1998; 46(5): 447-452.
14. Longo CM. The role of excess weight in antibiotic treatment failure. McGill University Libraries: Montreal, 2011.
15. Government of Canada. Canadian Integrated Program for Antimicrobial Resistance Surveillance (CIPARS), 2006. Public Health Agency of Canada: Guelph, ON, 2009.
16. The Center for Healthcare Research & Transformation. Price of Care Issue Brief: Antibiotic Prescribing and Use. University of Michigan: Michigan, 2011.
17. Sanchez Garcia M. Early antibiotic treatment failure. Int J Antimicrob Agents 2009; 34(Suppl 3): S14-19.
18. Cattan P, Yin DD, Sarfati E, Lyu R, De Zelicourt M, Fagnani F. Cost of care for inpatients with community-acquired intra-abdominal infections. Eur J Clin Microbiol Infect Dis 2002; 21(11): 787-793.
19. Mayo N, Daskalopoulou S, Nadeau L, et al. Risk factors for stroke: masked by age and sex? Abstracts From the 1st Canadian Stroke Congress 2012, 2012; e473-e510.
20. Bellerose C, Lavallée C, Chénard L, Levasseur M. Méthodes. Rapport de l'Enquête sociale et de Santé 1992-1993. Government of Quebec: Quebec, 1995.
21. Daveluy C, Pica L, Audet N, et al. Enquête sociale et de santé 1998. Institut de la statistique du Québec: Quebec, 2000.
22. Tamblyn R, Huang A, Kawasumi Y, et al. The development and evaluation of an integrated electronic prescribing and drug management system for primary care. J Am Med Inform Assoc 2006; 13(2): 148-159.
23. Monfared AA, Lelorier J. Accuracy and validity of using medical claims data to identify episodes of hospitalizations in patients with COPD. Pharmacoepidemiol Drug Saf 2006; 15(1): 19-29.
24. Bartlett G. Patterns of Benzodiazepine Use and Risk of Injury in the Elderly. McGill University: Montreal, 2001.
25. Gorber S, Shields M, Tremblay M, McDowell I. The feasibility of establishing correction factors to adjust self-reported estimates of obesity. Statistics Canada, 2008.
26. Chen C, Raut M, Shah M, et al. Antibiotic Failure/Modification Rates in the Treatment Of Community-Acquired Pneumonia (CAP) in the Outpatient Setting. Am J Respir Crit Care Med 2010; 181: A5493.
27. Menard SW. Applied Logistic Regression Analysis (2nd edn). Sage: Thousand Oaks, 2002.
28. Edelsberg J, Berger A, Schell S, Mallick R, Kuznik A, Oster G. Economic consequences of failure of initial antibiotic therapy in hospitalized adults with complicated intra-abdominal infections. Surg Infect (Larchmt) 2008; 9(3): 335-347.
29. Bergman SJ, Speil C, Short M, Koirala J. Pharmacokinetic and pharmacodynamic aspects of antibiotic use in high-risk populations. Infect Dis Clin North Am 2007; 21(3): 821-846, x.
30. Pai MP, Bearden DT. Antimicrobial dosing considerations in obese adult patients: Insights from the society of infectious diseases pharmacists. Pharmacotherapy 2007; 27(8): 1081-1091.
31. Bearden DT, Rodvold KA. Dosage adjustments for antibacterials in obese patients: applying clinical pharmacokinetics. Clin Pharmacokinet 2000; 38(5): 415-426.
32. Guillemot D, Carbon C, Balkau B, et al. Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA 1998; 279(5): 365-370.
33. Cleves MA, Sanchez N, Draheim M. Evaluation of two competing methods for calculating Charlson's comorbidity index when analyzing short-term mortality using administrative data. J Clin Epidemiol 1997; 50(8): 903-908.
34. Abdullahi M, Annibale B, Capoccia D, et al. The Eradication of Helicobacter pylori is Affected by Body Mass Index (BMI). Obes Surg 2008; 18(11): 1450-1454.
35. Halilovic J, Heintz BH, Brown J. Risk factors for clinical failure in patients hospitalized with cellulitis and cutaneous abscess. J Infect 2012; 65(2): 128-134.
36. Brügger-Andersen T, Pönitz V, Snapinn S, Dickstein K, OPTIMAAL study group. Moderate alcohol consumption is associated with reduced long-term cardiovascular risk in patients following a complicated acute myocardial infarction. Int J Cardiol 2009; 133(2): 229-232.
37. Namiot Z, Namiot DB, Kemona A, Golebiewska M, Bucki R. The effect of cigarette smoking and alcohol consumption on efficacy of Helicobacter pylori eradication. Pol Arch Med Wewn. 2000; 104(3): 569-574.
38. McAdams MA, Van Dam RM, Hu FB. Comparison of self-reported and measured BMI as correlates of disease markers in US adults. Obesity (Silver Spring) 2007; 15(1): 188-196.
39. Katzmarzyk PT, Perusse L, Malina RM, Bouchard C. Seven-year stability of indicators of obesity and adipose tissue distribution in the Canadian population. Am J Clin Nutr 1999; 69(6): 1123-1129.
40. Bruns AH, Oosterheert JJ, Hustinx WN, Gaillard CA, Hak E, Hoepelman AI. Time for first antibiotic dose is not predictive for the early clinical failure of moderate-severe community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2009; 28(8): 913-919.